{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:24:52Z","timestamp":1791987892682,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tufts in the Davis Program"},{"name":"Amyloidosis and Myeloma Research Fund at Tufts"},{"name":"Sidewater Family Fund"},{"DOI":"10.13039\/100009269","name":"Amyloidosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Demarest Lloyd Jr. Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.blre.2020.100720","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T03:11:22Z","timestamp":1592881882000},"page":"100720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types"],"prefix":"10.1016","volume":"45","author":[{"given":"Cindy","family":"Varga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Polydefkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovasc Pathol"},{"issue":"12","key":"10.1016\/j.blre.2020.100720_bb0015","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry."},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"issue":"24","key":"10.1016\/j.blre.2020.100720_bb0025","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/13506129.2014.964858","article-title":"Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis","volume":"21","author":"Sipe","year":"2014","journal-title":"Amyloid"},{"issue":"10038","key":"10.1016\/j.blre.2020.100720_bb0040","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM"},{"issue":"16","key":"10.1016\/j.blre.2020.100720_bb0050","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2012-03-413682","article-title":"How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 nomenclature guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"issue":"10","key":"10.1016\/j.blre.2020.100720_bb0060","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.blre.2020.100720_bb0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0070","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"25","key":"10.1016\/j.blre.2020.100720_bb0075","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","article-title":"Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis","volume":"32","author":"Weiss","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.blre.2020.100720_bb0080","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/hmg\/ddi051","article-title":"Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease","volume":"14","author":"Soares","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.blre.2020.100720_bb0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000154146","article-title":"Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence","volume":"43","author":"Sousa","year":"1993","journal-title":"Hum. Hered."},{"issue":"7","key":"10.1016\/j.blre.2020.100720_bb0095","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.blre.2020.100720_bb0100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mgg3.231","article-title":"The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa","volume":"4","author":"Jacobson","year":"2016","journal-title":"Mol Genet Genomic Med"},{"issue":"21","key":"10.1016\/j.blre.2020.100720_bb0105","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"10.1016\/j.blre.2020.100720_bb0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis: epidemiology, diagnosis, and management","volume":"6","author":"Real de Asua","year":"2014","journal-title":"Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.blre.2020.100720_bb0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0130","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0135","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ki.2014.11","article-title":"Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis","volume":"86","author":"Larsen","year":"2014","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0140","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases","volume":"8","author":"Said","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0145","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ki.2010.9","article-title":"Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies","volume":"77","author":"Larsen","year":"2010","journal-title":"Kidney Int."},{"issue":"15","key":"10.1016\/j.blre.2020.100720_bb0150","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2009-04-202879","article-title":"How I treat amyloidosis","volume":"114","author":"Comenzo","year":"2009","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2020.100720_bb0155","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.blre.2020.100720_bb0160","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0165","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1021\/acs.jproteome.5b00015","article-title":"Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies","volume":"14","author":"Dasari","year":"2015","journal-title":"J. Proteome Res."},{"issue":"24","key":"10.1016\/j.blre.2020.100720_bb0170","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100720_bb0175","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2010.1.287","article-title":"Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy","volume":"2010","author":"Cohen","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0185","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1309\/AJCPR2M4EUYNHLGM","article-title":"Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?","volume":"131","author":"Abadie","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.blre.2020.100720_bb0190","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.blre.2020.100720_bb0195","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.blre.2020.100720_bb0200","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0205","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100720_bb0210","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.blre.2020.100720_bb0215","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"30","author":"Merlini","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2020.100720_bb0220","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.amjcard.2014.07.026","article-title":"Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis","volume":"114","author":"Cyrille","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0225","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"19","key":"10.1016\/j.blre.2020.100720_bb0230","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0235","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1540-8175.2012.01680.x","article-title":"Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography","volume":"29","author":"Baccouche","year":"2012","journal-title":"Echocardiography"},{"issue":"16","key":"10.1016\/j.blre.2020.100720_bb0240","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0250","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ehjci\/jew101","article-title":"Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis","volume":"17","author":"Bhatti","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0255","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00259-018-4123-z","article-title":"Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis","volume":"46","author":"Treglia","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0260","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0265","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J. Nucl. Cardiol."},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0270","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3324\/haematol.2012.068155","article-title":"Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience","volume":"98","author":"Cowan","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2020.100720_bb0275","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199008233230803","article-title":"Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component","volume":"323","author":"Hawkins","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0280","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0285","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ajh.25149","article-title":"Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment","volume":"93","author":"Gertz","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"13","key":"10.1016\/j.blre.2020.100720_bb0290","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2020.100720_bb0295","article-title":"Amyloidosis: is a cure possible?","volume":"19","author":"Merlini","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.blre.2020.100720_bb0300","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/978-94-007-5416-4_22","article-title":"The challenge of systemic immunoglobulin light-chain amyloidosis (Al)","volume":"65","author":"Palladini","year":"2012","journal-title":"Subcell. Biochem."},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0305","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int."},{"issue":"15","key":"10.1016\/j.blre.2020.100720_bb0310","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100720_bb0315","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.blre.2020.100720_bb0320","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1002\/art.22959","article-title":"Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival","volume":"56","author":"Prokaeva","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0325","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.15885","article-title":"Stigmata of amyloidosis; external manifestations of internal disease","volume":"186","author":"Chaulagain","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0330","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2016-02-702696","article-title":"Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis","volume":"128","author":"Kastritis","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2020.100720_bb0335","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","article-title":"Wild-type transthyretin-derived amyloidosis in various ligaments and tendons","volume":"42","author":"Sueyoshi","year":"2011","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0340","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0345","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/ajcp\/97.2.250","article-title":"Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type","volume":"97","author":"Kyle","year":"1992","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.blre.2020.100720_bb0350","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13506120209114102","article-title":"Senile systemic amyloidosis presenting as bilateral carpal tunnel syndrome","volume":"9","author":"Takei","year":"2002","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0355","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.blre.2020.100720_bb0360","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","article-title":"High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly","volume":"42","author":"Sekijima","year":"2011","journal-title":"Hum. Pathol."},{"issue":"17","key":"10.1016\/j.blre.2020.100720_bb0365","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.blre.2020.100720_bb0370","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0375","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1212\/WNL.42.6.1157","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy","volume":"42","author":"Bromberg","year":"1992","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0380","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0385","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.510250122","article-title":"Hepatic amyloidosis: clinical appraisal in 77 patients","volume":"25","author":"Gertz","year":"1997","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.blre.2020.100720_bb0390","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJM197911083011907","article-title":"Factor X deficiency in primary amyloidosis: resolution after splenectomy","volume":"301","author":"Greipp","year":"1979","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0395","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","article-title":"Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy","volume":"97","author":"Choufani","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100720_bb0400","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"23","key":"10.1016\/j.blre.2020.100720_bb0405","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood.V126.23.188.188","article-title":"Results of phase I study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis","volume":"126","author":"Langer","year":"2015","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.blre.2020.100720_bb0410","doi-asserted-by":"crossref","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","article-title":"Novel antibody for the treatment of transthyretin amyloidosis","volume":"291","author":"Hosoi","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.blre.2020.100720_bb0415","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2020.100720_bb0420","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0425","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/mcp.2010.0480","article-title":"Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score","volume":"86","author":"Kumar","year":"2011","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.blre.2020.100720_bb0430","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0435","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2020.100720_bb0440","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1182\/blood.V122.21.3328.3328","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 19 Year experience at a single center","volume":"122","author":"Sanchorawala","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100720_bb0445","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0450","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0455","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.blre.2020.100720_bb0460","first-page":"2086","article-title":"Oligonucleotide drugs for transthyretin amyloidosis","volume":"379","author":"Buxbaum","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.blre.2020.100720_bb0465","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2019.37.15_suppl.8010","article-title":"Seeking light-chain amyloidosis very early: The SAVE trial\u2014identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma","volume":"37","author":"Zhou","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.blre.2020.100720_bb0470","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25244","article-title":"MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms","volume":"93","author":"Kourelis","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.blre.2020.100720_bb0475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.blre.2020.100720_bb0480","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.blre.2020.100720_bb0485","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V128.22.3261.3261","article-title":"Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2020.100720_bb0490","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2019-131863","article-title":"The use of next generation gene sequencing to measure minimal residual disease in patients with AL amyloidosis and low plasma cell burden: a feasibility study","volume":"134","author":"Sarosiek","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100720_bb0495","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","article-title":"Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis","volume":"44","author":"Donnelly","year":"2019","journal-title":"J Hand Surg [Am.]"},{"issue":"1","key":"10.1016\/j.blre.2020.100720_bb0500","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","article-title":"Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2020.100720_bb0505","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCIMAGING.113.001396","article-title":"How to image cardiac amyloidosis","volume":"7","author":"Falk","year":"2014","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:36Z","timestamp":1759436916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":101,"alternative-id":["S0268960X20300709"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100720","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100720"}}